As the general population continues to age, atrial and ventricular arrhythmias are of a growing concern. Despite modern technology, pharmacotherapy utilizing antiarrhythmic medications remains a ...

Sotalol is a class III antiarrhythmic drug and acts by blocking cardiac potassium channels. Sotalol also has nonselective beta-blocker properties. Sotalol exhibits “reverse use-dependence,” meaning at ...

Arbor announced that the FDA has approved Sotylize (sotalol HCl) oral solution for the treatment of documented life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in ...

Arbor announced the launch of Sotylize (sotalol HCl) oral solution for the treatment of life-threatening ventricular arrhythmias and for the maintenance of normal sinus rhythm in patients with highly ...

Sotalol (So), a new antiarrhythmic agent, is a beta-blocker that also has been shown to have some class III electrophysiologic (EP) effects. To evaluate the EP effects of So on the immature heart and ...

The Antiarrhythmics A fter Ablation of Atrial Fibrillation (5A) study suggests that such drug therapy aimed at preventing recurrences after AF ablation, which is commonly but not universally done and ...

Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular ...